Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 45

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016', provides in depth analysis on Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted pipeline therapeutics.

The report provides comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

  • The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Overview 6
Therapeutics Development 7
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Stage of Development 7
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Therapy Area 8
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Indication 9
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Companies 13
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development 21
Ampio Pharmaceuticals, Inc. 21
Bristol-Myers Squibb Company 22
Cyano Biotech GmbH 23
Lixte Biotechnology Holdings, Inc. 24
Signum Biosciences, Inc. 25
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles 26
Drugs to Activate PP2A for Oncology - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
DT-1154 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
LB-100 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
NCE-001 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecules to Activate PP2A for Parkinson Disease and Alzheimer's Disease - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Inhibit PP1 and PP2A for Oncology - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
VEL-015 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Projects 36
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Featured News & Press Releases 37
Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression 37
Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity 37
Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks To Enhance Development Of Its Pipeline Of Novel Compounds 38
Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies 38
Jan 23, 2015: Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 39
Nov 06, 2014: Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch 39
Jun 18, 2014: Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer 40
Apr 25, 2013: Lixte Biotechnology Initiates Phase I Trial Of Its Lead Anti-Cancer Compound LB-100 41
Jul 31, 2012: Lixte Biotechnology Announces Increased Funding And FDA Allowance To Conduct Phase I Trial Of LB-100 41
Jul 16, 2012: Ampio Pharma Advances NCE001 Cancer Drug Into Preclinical Development 41
May 01, 2012: Lixte Submits Investigational New Drug Application To FDA For Approval Of Clinical Trial Of LB-100 42
Sep 22, 2011: Lixte Biotechnology Receives US Patent For LB-100 42
Oct 05, 2010: Lixte Collaborates With NCI For Clinical Evaluation Of LB-100 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 21
Pipeline by Bristol-Myers Squibb Company, H2 2016 22
Pipeline by Cyano Biotech GmbH, H2 2016 23
Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 24
Pipeline by Signum Biosciences, Inc., H2 2016 25
Dormant Projects, H2 2016 36

List of Figures

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Top 10 Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Mechanism of Actions, H2 2016 16
Number of Products by Stage and Mechanism of Actions, H2 2016 16
Number of Products by Routes of Administration, H2 2016 18
Number of Products by Stage and Routes of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
  • Global Luxury Apparels Market To Do Well Owing To Numerous International Brands
    The global luxury apparels market is fired by the intensifying number of fashion marques and many designers getting wide-ranging clienteles in the form of cost-effective products. The global luxury apparels market was at US$1, 8842.69 million in 2015 and is forecast to reach US$60,793.7 million by the end of 2024. This segment of luxury goods [...]
  • Global Health and Wellness Market Boosted By Organic Products and Wearables
    Healthcare has constantly been a profitable area where buyers spend belligerently. But now, with increasing disposable earnings amid the city population and ground-breaking approaches and innovative products being developed, the overall health and wellness market is estimated for a healthy prospect. The health and wellness market is presently very dynamic owing to growing alertness amongst [...]
  • Increasing New Outlets And Striking Offers To Drive Global Pizza Market
    The global pizza market is predicted to grow at a steady CAGR of about 3% by 2020. Pizza has been gaining massive acceptance globally in the last few years. Consequently, the global pizza market is anticipated to observer considerable progress in the coming years. The growing number of pizzerias is one of the major elements [...]
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Global Collagenase Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 28-Nov-2016        Price: US 3480 Onwards        Pages: 110
    Collagenase, obtained from Clostridium histolyticum, is an enzyme used for tissue dissociation in vitro and thus for isolation of many different types of cells. These isolated cells are then used for numerous clinical and research applications.Scope of the Report:This report focuses on the Collagenase in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regi......
  • Alpha Glucosidase Inhibitors -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Alpha Glucosidase Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Alpha Glucosidase Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, c......
  • GABA Transaminase Inhibitors -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "GABA Transaminase Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the GABA Transaminase Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, c......
  • Plasminogen Activators -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Plasminogen Activators-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Plasminogen Activators. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaboration......
  • GABAB Modulators -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "GABAB Modulators-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the GABAB Modulators. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisiti......
  • Polo-Like Kinase 1 (PLK1 )Inhibitors -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Polo-Like Kinase 1 (PLK1 )Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Polo-Like Kinase 1 (PLK1 )Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technolo......
  • Gamma Secretase inhibitors -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Gamma Secretase inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Gamma Secretase inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, colla......
  • Poly (ADP-Ribose) Polymerase 1 (PARP-1) Inhibitors -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Poly (ADP-Ribose) Polymerase 1 (PARP-1) Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Poly (ADP-Ribose) Polymerase 1 (PARP-1) Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development a......
  • Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development a......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs